Davis R M Inc. Sells 12,873 Shares of Zoetis Inc. $ZTS

Davis R M Inc. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 11.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 101,827 shares of the company’s stock after selling 12,873 shares during the period. Davis R M Inc.’s holdings in Zoetis were worth $14,899,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Zoetis during the second quarter valued at approximately $809,491,000. Diamond Hill Capital Management Inc. purchased a new stake in Zoetis during the 3rd quarter valued at $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the period. Corient Private Wealth LLC grew its holdings in Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after acquiring an additional 1,191,840 shares during the last quarter. Finally, Impax Asset Management Group plc increased its position in shares of Zoetis by 362.6% in the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating on the stock. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Finally, Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

ZTS stock opened at $131.06 on Monday. The firm has a 50 day moving average price of $126.05 and a 200-day moving average price of $133.92. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The firm has a market capitalization of $55.32 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.00 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.